University of Pittsburgh researchers have identified a potential treatment for PACS1 and PACS2 Syndromes, severe neurodevelopmental diseases caused by mutations in the PACS1 (Arg203Trp) and PACS2 (Glu209Lys) genes. The research reveals altered interactions between the PACS1 and PACS2 disease variants and the histone deacetylase HDAC6. Experiments using patient-derived fibroblasts show that inhibiting HDAC6 with tubacin can reverse cellular defects associated with these syndromes. This discovery highlights the therapeutic potential of HDAC6 inhibitors for treating PACS1 and PACS2 Syndromes, which currently have no available therapies.

